Diagnostic Development News Today

We have to have a better understanding from the israelis about what they want to do. We have had several staff talks with them. We intend to do that more. They have assured us they were not going to rafah until we have had a chance to share our concerns with them. Reporter there have been working level conversations between the israelis and the Biden Administration over the last several weeks about the administrations concerns and thoughts about what israel could do differently in rafah. We are ...

INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a...

The investment includes building extensive manufacturing, production and diagnostic laboratory facilities at its global headquarters in Craigavon

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

/PRNewswire/ -- The "Advances in Gene Editing Technologies in Healthcare" report has been added to ResearchAndMarkets.coms offering. CRISPR, ZFNs, and TALENs...

Toronto, ON (PRWEB) November 01, 2022 -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical

WHO and MPP announce agreement with NIH for COVID-19 health technologies12 May 2022 Geneva – WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalised a licensing agreement with the United States National Institutes of Health (NIH) for the development of sever...

Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine - read this article along with other careers information, tips and advice on BioSpace

Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC populationOral presentation by Dr. Tanguy Y. Seiwert with comprehensive review of local and systemic potential effects of NBTXR3...